[1]罗朝学,黄定德,刘开元,等.131I治疗303例Graves病早期变化分析[J].陆军军医大学学报(原第三军医大学学报),2007,29(07):635-637.
 LUO Chao-xue,HUANG Ding-de,LIU Kai-yuan,et al.Inchoate changes in 303 cases of Graves disease treated with 131I[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(07):635-637.
点击复制

131I治疗303例Graves病早期变化分析(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
29卷
期数:
2007年第07期
页码:
635-637
栏目:
论著
出版日期:
2007-04-15

文章信息/Info

Title:
Inchoate changes in 303 cases of Graves disease treated with 131I
作者:
罗朝学黄定德刘开元李前伟
第三军医大学西南医院核医学科
Author(s):
LUO Chao-xue HUANG Ding-de LIU Kai-yuan LI Qian-wei
Department of Nuclear Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
关键词:
Graves病放射性碘甲状腺激素
Keywords:
Graves disease radioiodine thyroid hormones
分类号:
R581.105; R817.5
文献标志码:
A
摘要:
目的     探讨131I治疗甲亢早期动态变化,评价其治疗效果。     方法     对303例接受131I治疗的甲亢患者,在治疗后6个月分别进行了随访,了解其症状、体征及用放射免疫法和免疫放射分析法测定的血清甲状腺激素浓度,并对结果进行统计学处理。     结果     治疗前和治疗后6个月症状、体征明显改善,各激素值较治疗时均有明显变化,且差别都有显著的统计学意义(P<0.05),新增6例突眼患者。303例患者中,249例(82.2%)痊愈,21例(6.9%)好转,24例(7.9%)出现甲低,9例(3.0%)无效。总有效率为97.3%,治愈率为90.1%。     结论     131I治疗甲亢经济、简便、安全、有效,可作为Graves病的首选治疗方法。
Abstract:
Objective     To explore the inchoate changes in patients with Graves disease (GD) treated with 131I and appraise the therapeutic effect.      Methods     According to the thyroid size, patients’ age, thyroid 131I intake rate and course of the disease, 303 patients with GD were given individual 131I doses. Six months later, the symptom, signs, and thyroid hormone levels of every case were compared with those recorded before.      Results     The symptom and the level of thyroid hormones were significantly meliorated after 131I  treatment. Six cases became goggle-eyed after treatment. Among the 303 patients, 249(82.18%) fully recovered, 21 (6.93%) partially remitted, 24(7.92%) developed hypothyroidism, and 9(2.97%) showed ineffective.      Conclusion     131I treatment for GD with an individual dose can exert a satisfied therapeutic efficacy. It may as serve the first choice for GD treatment.

相似文献/References:

[1]吴平,李华,易吉秀,等.2种剂量131I治疗Graves病的前瞻性随机对照研究[J].陆军军医大学学报(原第三军医大学学报),2012,34(16):1677.
 Wu Ping,Li Hua,Yi Jimei,et al.Therapeutic effect of 131-iodine at 2 different doses for Graves’ disease: a randomized controlled trial[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(07):1677.
[2]江学容,谭兴容,鲁远彪,等.131I治疗Graves病的远期效果随访研究[J].陆军军医大学学报(原第三军医大学学报),2012,34(16):1689.
[3]王燕,朱中桃.肝豆状核变性合并Graves病周期性麻痹1例[J].陆军军医大学学报(原第三军医大学学报),2010,32(04):407.
[4]黎南中,文玉梅,程时武,等.Graves病、黑棘皮病合并B型胰岛素抵抗综合征1例[J].陆军军医大学学报(原第三军医大学学报),2011,33(02):189.
[5]郭莲,张先祥.Graves病患者131I治疗前后血清TNF-α和TRAb水平的变化及其相关性研究[J].陆军军医大学学报(原第三军医大学学报),2013,35(14):1528.
 Guo Lian,Zhang Xianxiang.Changes and correlation of serum levels of TNF-α and TRAb in patients with Graves’ disease before and after 131I treatment[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(07):1528.
[6]杨士军,崔兆辉,陆卫平.Graves病患者血清Ghrelin水平与甲状腺功能状态的关系[J].陆军军医大学学报(原第三军医大学学报),2010,32(24):2668.
[7]肖蓉,黄和银,周泽华,等.Graves病患者心率变异性分析[J].陆军军医大学学报(原第三军医大学学报),2003,25(17):0.[doi:10.16016/j.1000-5404.2003.17.013 ]

更新日期/Last Update: 2008-10-28